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FOREWORD
Combating antimicrobial resistance: a challenge
for medicine and public health
The emergence of antimicrobial resistance poses a
challenge for clinical medicine and public health
both in the United States and globally. In the USA,
for example, Centers for Disease Control and Pre-
vention (CDC) surveillance data indicate that over
25% of isolates of invasive Streptococcus pneumoniae
are no longer susceptible to penicillin, and multi-
drug resistance is increasing. Over 50% of Staphy-
lococcus aureus infections acquired in US intensive-
care units are now resistant to methicillin, and
methicillin-resistant strains are also being reported
in community-acquired infections. In 2000, 21% of
non-typhoidal salmonella infections in humans
were multidrug resistant. Drug resistance rates
for these and other pathogens, e.g. tuberculosis,
malaria, and human immunodeﬁciency virus, are
increasing in many countries.
Combating antimicrobial resistance requires a
multifaceted approach, as outlined in the World
Health Organization (WHO) Global Strategy for
Containment of Antimicrobial Resistance (http://
www.who.int/emc/amrpdfs/WHO_Global_Stra-
tegy_English.pdf), the US Public Health Action
Plan to Combat Antimicrobial Resistance (http://
www.cdc.gov/drugresistance/actionplan/index.
htm), the Report of the European Union Confer-
ence on the Microbial Threat (http://www.sum.
dk/publika/micro98/), and similar documents
published in other countries. These plans form
the basis for transforming antimicrobial resist-
ance from an urgent to a routine and manageable
problem through co-ordinated national and global
efforts. Important elements include surveillance,
prevention and control programs, research, and
development of new products (e.g. drugs and
vaccines).
The papers in this volume focus on the impact of
drug resistance on respiratory infections, a com-
mon cause of illness and death world-wide. They
explore the factors driving resistance, particularly
antimicrobial drug use, and opportunities for
intervention. Prevention and control strategies
include promoting appropriate antibiotic use
and reducing infection transmission, e.g. with
vaccines. Progress in reducing inappropriate anti-
biotic use is encouraging, e.g. prescribing rates for
children in the USA have declined, coinciding
with a national campaign to promote the appro-
priate use of antibiotics; similar successes have
been reported in Europe, Canada, and Australia.
Information on CDC antimicrobial resistance
activities, including surveillance data, prevention
and control programs, and a new interactive web
page for clinical laboratory personnel (MASTER)
are available at http://www.cdc.gov/drugresis-
tance. By forming effective partnerships both
nationally and globally to spur research and
new drug development and to enhance surveil-
lance and prevention and control interventions,
we can reduce the threat of antimicrobial resis-
tance for patients today and for future generations.
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